Stay updated on Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The clinical trial record for cabozantinib versus paclitaxel in recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer is displayed, including its study design, eligibility criteria, outcome measures, and participating locations. The record also includes publication and study history details.
    Difference
    100%
    Check dated 2026-11-07T12:40:18.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0, while the study record remains inaccessible behind a 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-31T13:24:44.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    A general NIH banner announces a website transition and a temporary change in terminology from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T14:59:32.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The site footer revision label changed from v3.7.1 to v3.7.2; the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T14:50:22.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label changes from v3.7.0 to v3.7.1. The page remains a 403 error screen.
    Difference
    0.2%
    Check dated 2026-10-10T15:51:47.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error with header and footer intact, indicating access to the study record is blocked.
    Difference
    18%
    Check dated 2026-09-19T19:09:11.000Z thumbnail image

Stay in the know with updates to Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page.